ITM Isotope Technologies Munich's subsidiary ITM Medical Isotopes and biopharmaceutical company Molecular Targeting Technologies (MTTI) have signed a supply deal for no-carrier-added lutetium-177 (Lu-177).
ITM will provide Lu-177 to MTTI for the preclinical and clinical development and potential commercial production of MTTI's radiopharmaceutical candidate Lu-177 EBTATE to treat a range of cancers.
Currently, Lu-177 EBTATE is in clinical development for the treatment of neuroendocrine tumors, a special form of thyroid cancer, and nasopharyngeal cancer. The radiopharmaceutical is to be used in targeted radionuclide therapy, a precise approach to directly target and destroy tumor tissue with minimal effect on surrounding healthy tissue.